| Literature DB >> 26379729 |
Hyun Joon An1, Woo Young Shin1, Keon-Young Lee1, Seung-Ik Ahn1.
Abstract
BACKGROUNDS/AIMS: Intrahepatic recurrence is one of the most important causes of compromised prognosis after surgical resection of hepatocellular carcinoma (HCC). This retrospective study was designed to identify and compare the risks of recurrence, early recurrence and multiple recurrences in a single patient population.Entities:
Keywords: Hepatocellular carcinoma; Recurrence pattern; Resection; Risk factors
Year: 2015 PMID: 26379729 PMCID: PMC4568596 DOI: 10.14701/kjhbps.2015.19.3.89
Source DB: PubMed Journal: Korean J Hepatobiliary Pancreat Surg ISSN: 1738-6349
Inclusion and exclusion criteria
HCC, hepatocellular carcinoma; TACE, transarterial chemoembolization; RFA, radiofrequency ablation
Comparisons of the demographic data and clinicopathological factors of single nodular hepatocellular carcinoma patients, with or without recurrence
*Maximum value was set to 40,000 ng/ml. **Maximum value was set to 2,000 mAU/ml. ***Tumor staging according to 7th AJCC tumor staging system. HBV, hepatitis B virus; HCV, hepatitis C virus; ALC, alcoholic liver disease; MELD, model for end-stage liver disease; AFP, alpha-fetoprotein; PIVKA, protein induced by vitamin K absence or antagonist
Factors of recurrence identified by the multivariate analysis (Cox proportional hazard model)
CI, confidence interval; pT stage, pathologic tumor stage
Fig. 1Comparison of postoperative recurrence-free survival curves, according to the pathological tumor staging.
Factors of early recurrence identified by the multivariate analysis (≤18 months, logistic regression analysis)
CI, confidence interval
Fig. 2Comparison of postoperative recurrence-free survival curves, between groups of single versus multiple recurrent nodules (A), and fewer (≤3) versus diffuse (>3) recurrent nodules (B).
Fig. 3Distribution of the number of recurrent tumor nodules in the 41 patients with HCC recurrence.
Comparison of the risk factors of recurrence in the early/late subgroups (with cutoffs of 18 months or 10 months), and the nodule multiplicity subgroups (with cutoffs of 1 or 3 nodules)
*Independent risk factors. AFP, alpha-fetoprotein; MELD, model for end-stage liver disease